A detailed history of Delta Investment Management, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Delta Investment Management, LLC holds 4,528 shares of BMY stock, worth $266,563. This represents 0.05% of its overall portfolio holdings.

Number of Shares
4,528
Holding current value
$266,563
% of portfolio
0.05%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $179,580 - $234,324
4,528 New
4,528 $234,000
Q1 2024

May 08, 2024

SELL
$47.98 - $54.4 $6,333 - $7,180
-132 Reduced 2.92%
4,383 $237,000
Q4 2023

Feb 02, 2024

SELL
$48.48 - $57.85 $9,792 - $11,685
-202 Reduced 4.28%
4,515 $231,000
Q1 2023

May 05, 2023

SELL
$65.71 - $74.53 $1,117 - $1,267
-17 Reduced 0.36%
4,717 $326,000
Q4 2022

Jan 19, 2023

BUY
$68.48 - $81.09 $136 - $162
2 Added 0.04%
4,734 $0
Q3 2022

Oct 21, 2022

BUY
$0.13 - $76.84 $62 - $36,883
480 Added 11.29%
4,732 $336,000
Q2 2021

Aug 06, 2021

BUY
$61.91 - $67.42 $1,238 - $1,348
20 Added 0.47%
4,252 $284,000
Q4 2020

Feb 04, 2021

SELL
$57.74 - $65.43 $2,309 - $2,617
-40 Reduced 0.94%
4,232 $262,000
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $2,297 - $2,545
40 Added 0.95%
4,272 $257,000
Q2 2020

Aug 05, 2020

SELL
$54.82 - $64.09 $1,644 - $1,922
-30 Reduced 0.7%
4,232 $248,000
Q1 2020

May 14, 2020

SELL
$46.4 - $67.43 $64,171 - $93,255
-1,383 Reduced 24.5%
4,262 $237,000
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $48,767 - $63,612
991 Added 21.29%
5,645 $362,000
Q3 2019

Nov 05, 2019

SELL
$42.77 - $50.71 $26,046 - $30,882
-609 Reduced 11.57%
4,654 $236,000
Q2 2019

Aug 08, 2019

BUY
$44.62 - $49.34 $234,835 - $259,676
5,263 New
5,263 $238,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Delta Investment Management, LLC Portfolio

Follow Delta Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Delta Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Delta Investment Management, LLC with notifications on news.